NASDAQ:BNR - Burning Rock Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $39.94
  • Forecasted Upside: 208.66 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$12.94
▼ -0.24 (-1.82%)

This chart shows the closing price for BNR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Burning Rock Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNR

Analyst Price Target is $39.94
▲ +208.66% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Burning Rock Biotech in the last 3 months. The average price target is $39.94, with a high forecast of $39.94 and a low forecast of $39.94. The average price target represents a 208.66% upside from the last price of $12.94.

This chart shows the closing price for BNR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Burning Rock Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2021CowenInitiated CoverageOutperformHigh
7/14/2021CICC ResearchInitiated CoverageOutperform$39.94High
7/13/2020Bank of AmericaInitiated CoverageBuy$32.30Low
7/7/2020Morgan StanleyInitiated CoverageOverweightHigh
7/7/2020CowenInitiated CoverageOutperformHigh
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/22/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
10/22/2021

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Burning Rock Biotech logo
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Read More

Today's Range

Now: $12.94
Low: $12.32
High: $13.76

50 Day Range

MA: $18.91
Low: $14.30
High: $22.60

52 Week Range

Now: $12.94
Low: $13.11
High: $39.75

Volume

13,592 shs

Average Volume

240,373 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Burning Rock Biotech?

The following Wall Street research analysts have issued reports on Burning Rock Biotech in the last year: CICC Research, Cowen Inc, and Zacks Investment Research.
View the latest analyst ratings for BNR.

What is the current price target for Burning Rock Biotech?

1 Wall Street analysts have set twelve-month price targets for Burning Rock Biotech in the last year. Their average twelve-month price target is $39.94, suggesting a possible upside of 208.7%. CICC Research has the highest price target set, predicting BNR will reach $39.94 in the next twelve months. CICC Research has the lowest price target set, forecasting a price of $39.94 for Burning Rock Biotech in the next year.
View the latest price targets for BNR.

What is the current consensus analyst rating for Burning Rock Biotech?

Burning Rock Biotech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNR will outperform the market and that investors should add to their positions of Burning Rock Biotech.
View the latest ratings for BNR.

What other companies compete with Burning Rock Biotech?

How do I contact Burning Rock Biotech's investor relations team?

Burning Rock Biotech's physical mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The company's listed phone number is 86-185-0164-1666. The official website for Burning Rock Biotech is www.brbiotech.com.